Danielle Antalffy
Stock Analyst at UBS
(3.58)
# 754
Out of 4,829 analysts
164
Total ratings
46.94%
Success rate
5.41%
Average return
Main Sectors:
Stocks Rated by Danielle Antalffy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TMCI Treace Medical Concepts | Maintains: Neutral | $10 → $8.6 | $6.82 | +26.10% | 6 | May 9, 2025 | |
| ATRC AtriCure | Maintains: Buy | $60 → $58 | $31.00 | +87.10% | 13 | Apr 30, 2025 | |
| INMD InMode | Maintains: Neutral | $19 → $16 | $14.45 | +12.46% | 4 | Apr 29, 2025 | |
| RXST RxSight | Downgrades: Neutral | $45 → $16 | $13.06 | +22.51% | 3 | Apr 9, 2025 | |
| MDT Medtronic | Maintains: Neutral | $85 → $95 | $83.48 | +13.80% | 8 | Feb 19, 2025 | |
| BSX Boston Scientific | Maintains: Buy | $105 → $130 | $102.86 | +26.39% | 12 | Feb 7, 2025 | |
| SGHT Sight Sciences | Maintains: Buy | $5.5 → $5 | $3.08 | +62.34% | 2 | Jan 27, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $146 → $148 | $133.24 | +11.08% | 12 | Jan 23, 2025 | |
| GKOS Glaukos | Initiates: Buy | $182 | $89.96 | +102.31% | 1 | Dec 6, 2024 | |
| SYK Stryker | Maintains: Neutral | $366 → $370 | $380.92 | -2.87% | 6 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $75 | $73.68 | +1.79% | 12 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $112 → $107 | $95.21 | +12.38% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $163 → $95 | $84.67 | +12.20% | 8 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $33.05 | +126.93% | 1 | Jan 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $180 | $154.22 | +16.72% | 4 | Dec 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $405 → $322 | $151.25 | +112.89% | 5 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $2.25 | $2.23 | +0.90% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $43 | $30.90 | +39.16% | 5 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $278 | $536.51 | -48.18% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $45 | $22.98 | +95.82% | 14 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $300 → $280 | $310.67 | -9.87% | 12 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $975 → $825 | $15.08 | +5,370.82% | 2 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $11.37 | +23.19% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $100 | $81.74 | +22.34% | 2 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $12 | $12.95 | -7.30% | 3 | Mar 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $30 | $53.11 | -43.51% | 3 | Mar 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $41.72 | +7.86% | 4 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $270 → $275 | $167.22 | +64.45% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $3.06 | +553.59% | 3 | Nov 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $72 → $42 | $6.23 | +574.70% | 7 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $3 | $0.63 | +380.00% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $0.87 | +1,622.16% | 1 | Sep 1, 2020 |
Treace Medical Concepts
May 9, 2025
Maintains: Neutral
Price Target: $10 → $8.6
Current: $6.82
Upside: +26.10%
AtriCure
Apr 30, 2025
Maintains: Buy
Price Target: $60 → $58
Current: $31.00
Upside: +87.10%
InMode
Apr 29, 2025
Maintains: Neutral
Price Target: $19 → $16
Current: $14.45
Upside: +12.46%
RxSight
Apr 9, 2025
Downgrades: Neutral
Price Target: $45 → $16
Current: $13.06
Upside: +22.51%
Medtronic
Feb 19, 2025
Maintains: Neutral
Price Target: $85 → $95
Current: $83.48
Upside: +13.80%
Boston Scientific
Feb 7, 2025
Maintains: Buy
Price Target: $105 → $130
Current: $102.86
Upside: +26.39%
Sight Sciences
Jan 27, 2025
Maintains: Buy
Price Target: $5.5 → $5
Current: $3.08
Upside: +62.34%
Abbott Laboratories
Jan 23, 2025
Maintains: Buy
Price Target: $146 → $148
Current: $133.24
Upside: +11.08%
Glaukos
Dec 6, 2024
Initiates: Buy
Price Target: $182
Current: $89.96
Upside: +102.31%
Stryker
Oct 30, 2024
Maintains: Neutral
Price Target: $366 → $370
Current: $380.92
Upside: -2.87%
Sep 10, 2024
Maintains: Neutral
Price Target: $90 → $75
Current: $73.68
Upside: +1.79%
Aug 8, 2024
Maintains: Sell
Price Target: $112 → $107
Current: $95.21
Upside: +12.38%
Jul 26, 2024
Maintains: Buy
Price Target: $163 → $95
Current: $84.67
Upside: +12.20%
Jan 22, 2024
Initiates: Buy
Price Target: $75
Current: $33.05
Upside: +126.93%
Dec 1, 2023
Upgrades: Buy
Price Target: $180
Current: $154.22
Upside: +16.72%
Sep 6, 2023
Maintains: Buy
Price Target: $405 → $322
Current: $151.25
Upside: +112.89%
Mar 29, 2023
Initiates: Neutral
Price Target: $2.25
Current: $2.23
Upside: +0.90%
Mar 29, 2023
Initiates: Neutral
Price Target: $43
Current: $30.90
Upside: +39.16%
Mar 29, 2023
Initiates: Neutral
Price Target: $278
Current: $536.51
Upside: -48.18%
Mar 29, 2023
Initiates: Neutral
Price Target: $45
Current: $22.98
Upside: +95.82%
May 6, 2022
Maintains: Outperform
Price Target: $300 → $280
Current: $310.67
Upside: -9.87%
May 5, 2022
Maintains: Outperform
Price Target: $975 → $825
Current: $15.08
Upside: +5,370.82%
May 5, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $11.37
Upside: +23.19%
May 2, 2022
Maintains: Outperform
Price Target: $75 → $100
Current: $81.74
Upside: +22.34%
Mar 11, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $12.95
Upside: -7.30%
Mar 9, 2022
Maintains: Outperform
Price Target: $25 → $30
Current: $53.11
Upside: -43.51%
Feb 25, 2022
Maintains: Outperform
Price Target: $40 → $45
Current: $41.72
Upside: +7.86%
Feb 4, 2022
Maintains: Market Perform
Price Target: $270 → $275
Current: $167.22
Upside: +64.45%
Nov 10, 2021
Maintains: Outperform
Price Target: $26 → $20
Current: $3.06
Upside: +553.59%
Nov 5, 2021
Maintains: Market Perform
Price Target: $72 → $42
Current: $6.23
Upside: +574.70%
Apr 1, 2021
Downgrades: Market Perform
Price Target: $3
Current: $0.63
Upside: +380.00%
Sep 1, 2020
Initiates: Outperform
Price Target: $15
Current: $0.87
Upside: +1,622.16%